

## Special Issue

# Breast Cancer Radiotherapy: The State of the Art

### Message from the Guest Editor

Adjuvant breast radiotherapy improves local control and reduces cancer-specific mortality; however first-generation techniques were associated with an increased risk of long term toxicity, a direct consequence of the wide irradiation fields which were used at that time and which exposed substantial cardiac volumes. Breast radiotherapy has fortunately evolved; currently, cardiac sparing can be efficiently achieved thanks to state-of-the-art techniques such as rotational intensity modulated radiation therapy (IMRT) or protontherapy. New molecules are arriving in the breast cancer treatment and it is important to know the efficacy and toxicity of these associations. This Special Issue is trying to respond to some of these questions.

---

### Guest Editor

Dr. Youlia Kirova

Associate Professor of Radiation Oncology UVSQ, Department of Radiation Oncology, Institut Curie, 75005 Paris, France

---

### Deadline for manuscript submissions

closed (31 January 2022)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/70021](https://mdpi.com/si/70021)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)